MARKET

LYRA

LYRA

Lyra Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.45
+0.13
+2.44%
Closed 16:00 06/24 EDT
OPEN
5.40
PREV CLOSE
5.32
HIGH
5.53
LOW
5.21
VOLUME
230.45K
TURNOVER
883.10K
52 WEEK HIGH
9.98
52 WEEK LOW
3.300
MARKET CAP
173.45M
P/E (TTM)
-1.6585
1D
5D
1M
3M
1Y
5Y
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, t...
PR Newswire · 06/17 20:01
Lyra Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Lyra Therapeutics's (NASDAQ:LYRA) reported sales totaled $5.37 million. Despite a 48.51% increase in earnings, the company posted a loss of $7.01 million.
Benzinga · 06/10 15:42
Lyra Therapeutics to Present at Upcoming Investor Conferences
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, t...
PR Newswire · 05/26 11:00
Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor
Benzinga · 05/25 17:07
Lyra Therapeutics initiated with an overweight rating at Cantor Fitzgerald; sees 147% upside
Cantor Fitzgerald initiated Lyra Therapeutics (NASDAQ:LYRA) with an overweight rating saying the company's pipeline is not appreciated enough. The firm has a $15 price target (~147% upside based on Monday's
Seekingalpha · 05/24 16:55
--Cantor Fitzgerald Starts Lyra Therapeutics at Overweight With $15 Price Target
MT Newswires · 05/24 06:47
Lyra Therapeutics Files for Potential Secondary Offering of Up to 15.5 Million Common Shares
MT Newswires · 05/12 04:37
BRIEF-Lyra Therapeutics Files For Offering Of Up To 15.5 Million Shares Common Stock
reuters.com · 05/11 21:24
More
No Data
Learn about the latest financial forecast of LYRA. Analyze the recent business situations of Lyra Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

80.00%Strong Buy
0.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LYRA stock price target is 19.25 with a high estimate of 24.00 and a low estimate of 14.00.
High24.00
Average19.25
Low14.00
Current 5.45
EPS
Actual
Estimate
-0.84-0.63-0.42-0.21
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 32
Institutional Holdings: 6.13M
% Owned: 19.25%
Shares Outstanding: 31.83M
TypeInstitutionsShares
Increased
6
95.25K
New
2
750
Decreased
8
130.51K
Sold Out
8
76.29K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/Executive Director
Harlan Waksal
President/Chief Executive Officer/Director
Maria Palasis
Chief Financial Officer/Treasurer/Secretary
Jason Cavalier
Senior Vice President
Pamela Nelson
Senior Vice President
Corinne Noyes
Senior Vice President
Robert Richard
Lead Director/Independent Director
James Tobin
Independent Director
Michael Altman
Independent Director
Edward Anderson
Independent Director
C. Ann Merrifield
Independent Director
Konstantin Poukalov
Independent Director
W. Bradford Smith
Independent Director
Nancy Snyderman
No Data
No Data
About LYRA
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy. The Company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

Webull offers kinds of Lyra Therapeutics Inc stock information, including NASDAQ:LYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LYRA stock methods without spending real money on the virtual paper trading platform.